Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

Hvidovre University Hospital

Status: Completed

Conditions: Type-1 Diabetes Mellitus

Treatments: Other: glucose dependent insulinotropic polypeptide; Other: glucagon like peptide -1; Other: NaCl

Study type: Interventional

Funder types: Other

Identifiers

NCT00603031

H-D-2007-0076

2008-000305-11 (Other Identifier)

Details and patient eligibility

About

study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.

Enrollment: 9 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18-60 years
• Type-1 diabetes diagnosed between 5-40 years of age
• Normal weight(BMI 18-27),
• Insulin treatment from time of diagnosis.

Exclusion criteria

• Severe complications to diabetes
• Abnormal liver or kidney function
• Haemoglobin below the lower limit
• Macroalbuminuria
• Systemic disease
• Pregnancy.

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

9 participants in 3 patient groups, including a placebo group

GLP-1

Experimental group

Description:

time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).

Treatment:

Other: glucagon like peptide -1

NaCl

Placebo Comparator group

Description:

time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).

Treatment:

Other: NaCl

GIP

Experimental group

Description:

time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).

Treatment:

Other: glucose dependent insulinotropic polypeptide